THE R337C MUTATION GENERATES A HIGH KM 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-II ENZYME IN A FAMILY WITH APPARENT MINERALOCORTICOID EXCESS

被引:57
|
作者
OBEYESEKERE, VR
FERRARI, P
ANDREWS, RK
WILSON, RC
NEW, MI
FUNDER, JW
KROZOWSKI, ZS
机构
[1] BAKER MED RES INST, MOLEC HYPERTENS LAB, MELBOURNE, VIC 3181, AUSTRALIA
[2] BAKER MED RES INST, VASC BIOL LAB, MELBOURNE, VIC 3181, AUSTRALIA
[3] NEW YORK HOSP, CORNELL MED CTR, DEPT PEDIAT, DIV PEDIAT ENDOCRINOL, NEW YORK, NY USA
来源
关键词
D O I
10.1210/jc.80.11.3381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 11 beta-hydroxysteroid dehydrogenase type II enzyme (11 beta HSD2) inactivates glucocorticoids in the kidney and thus permits aldosterone to occupy the non-selective mineralocortiocid receptor in epithelial tissues. We have recently described a C to T transition in the HSD11B2 gene which results in an arginine to cysteine mutation (R337C) in the 11 beta HSD2 enzyme in a consanguineous family with three siblings suffering from Apparent Mineralocorticoid Excess (AME). In the present study we have examined the metabolism of cortisol in mammalian cells transfected with plasmids expressing the wild type and mutant enzymes. In whole cells the Km of the normal enzyme was 110nM, while the enzyme containing the R337C mutation displayed a Km of 1010nM. Further experiments revealed that the mutant was totally inactive in cell free preparations, suggesting that it has additional properties which may compromise its activity in whole cells.
引用
收藏
页码:3381 / 3383
页数:3
相关论文
共 12 条
  • [1] The 11 beta-hydroxysteroid dehydrogenase type II enzyme: Biochemical consequences of the congenital R337C mutation
    Ferrari, P
    Obeyesekere, VR
    Li, K
    Andrews, RK
    Krozowski, ZS
    STEROIDS, 1996, 61 (04) : 197 - 200
  • [3] MINERALOCORTICOID HYPERTENSION AND CONGENITAL DEFICIENCY OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE IN A FAMILY WITH THE SYNDROME OF APPARENT MINERALOCORTICOID EXCESS
    MILFORD, DV
    SHACKLETON, CHL
    STEWART, PM
    CLINICAL ENDOCRINOLOGY, 1995, 43 (02) : 241 - 246
  • [4] SEVERAL HOMOZYGOUS MUTATIONS IN THE GENE FOR 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2 IN PATIENTS WITH APPARENT MINERALOCORTICOID EXCESS
    WILSON, RC
    HARBISON, MD
    KROZOWSKI, ZS
    FUNDER, JW
    SHACKLETON, CHL
    HANAUSKEABEL, HM
    WEI, JQ
    HERTECANT, J
    MORAN, A
    NEIBERGER, RE
    BALFE, JW
    FATTAH, A
    DANEMAN, D
    LICHOLAI, T
    NEW, MI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (11): : 3145 - 3150
  • [5] IMMUNOHISTOCHEMICAL LOCALIZATION OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-II ENZYME IN HUMAN KIDNEY AND PLACENTA
    KROZOWSKI, Z
    MAGUIRE, JA
    STEINOAKLEY, AN
    DOWLING, J
    SMITH, RE
    ANDREWS, RK
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (07): : 2203 - 2209
  • [6] Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene
    Stewart, PM
    Krozowski, ZS
    Gupta, A
    Milford, DV
    Howie, AJ
    Sheppard, MC
    Whorwood, CB
    LANCET, 1996, 347 (8994): : 88 - 91
  • [7] APPARENT MINERALOCORTICOID EXCESS CAUSED BY A NOVEL MUTATION IN 11-β HYDROXYSTEROID DEHYDROGENASE TYPE 2 ENZYME: ITS GENETICS AND RESPONSE TO THERAPY
    Alzahrani, Ali S.
    Aljuhani, Nasser
    Qasem, Ebtesam
    Almohanna, Mai
    Hamoudh, Eman
    AlOmair, Abeer
    Alharbi, Naffaa
    ENDOCRINE PRACTICE, 2014, 20 (09) : E151 - E156
  • [8] A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess
    Kitanaka, S
    Katsumata, N
    Tanae, A
    Hibi, I
    Takeyama, KI
    Fuse, H
    Kato, S
    Tanaka, T
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (12): : 4054 - 4058
  • [9] DEFECTS IN THE HSD11 GENE ENCODING 11-BETA-HYDROXYSTEROID DEHYDROGENASE ARE NOT FOUND IN PATIENTS WITH APPARENT MINERALOCORTICOID EXCESS OR 11-OXOREDUCTASE DEFICIENCY
    NIKKILA, H
    TANNIN, GM
    NEW, MI
    TAYLOR, NF
    KALAITZOGLOU, G
    MONDER, C
    WHITE, PC
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (03): : 687 - 691
  • [10] Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess
    Ferrari, P
    Obeyesekere, VR
    Li, K
    Wilson, RC
    New, MI
    Funder, JW
    Krozowski, ZS
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1996, 119 (01) : 21 - 24